Development Of A Serum Based Test For Aggressive Prostate Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$144,950.00
Summary
Prostate cancer is relatively slow growing, taking decades to reach clinical significance. A critical phase in the progression of prostate cancer is the transformation from latent (or dormant) to aggressive tumours; hence the saying that many men die with prostate cancer, rather than of prostate cancer. We aim to develop a test utilising inhibin-activin proteins as surrogate markers of aggressive disease based on our previous studies of a significant correlation between the expression of inhibin ....Prostate cancer is relatively slow growing, taking decades to reach clinical significance. A critical phase in the progression of prostate cancer is the transformation from latent (or dormant) to aggressive tumours; hence the saying that many men die with prostate cancer, rather than of prostate cancer. We aim to develop a test utilising inhibin-activin proteins as surrogate markers of aggressive disease based on our previous studies of a significant correlation between the expression of inhibins in tissues from men with high grade prostate cancer. This study aims to validate the correlation using serum rather than a tissue based assay.Read moreRead less
Development Of Novel Reagents For The Point-of-care(field) Diagnosis &differentiation Of The Malaria Parasites, Plasmodi
Funder
National Health and Medical Research Council
Funding Amount
$117,000.00
Summary
Malaria is a major global health problem. 500 million people become infected with malaria parasites every year and 2-3 million people die each year from the disease. Rapid diagnosis of the disease is needed to allow correct treatment protocols. Increasingly protein-based immunochromatographic tests are being employed for the diagnosis of malaria as they offer significant advantages over classical thick smear tests, which require trained personnel and laboratory facilities. We propose to develop ....Malaria is a major global health problem. 500 million people become infected with malaria parasites every year and 2-3 million people die each year from the disease. Rapid diagnosis of the disease is needed to allow correct treatment protocols. Increasingly protein-based immunochromatographic tests are being employed for the diagnosis of malaria as they offer significant advantages over classical thick smear tests, which require trained personnel and laboratory facilities. We propose to develop a protein-based malaria diagnostic that has the ability to distinguish the two major human pathogens, P.falciparum and P. vivax.Read moreRead less
Q-Sand (TM): Whispering Gallery Mode Detection System For Ultrasensitive And Label Free Testing In Biotechnology.
Funder
National Health and Medical Research Council
Funding Amount
$127,750.00
Summary
Quantum Dots, a type of nanocrystal, have been shown to emit light at a very precise wavelength. Quantum dots of approximately 5 nm in diameter have been conjugated to a silica microsphere and then coated with free silica, thus encasing the Quantum Dots in a small chamber surrounding the microsphere. This structure is analogous to a light globe under a lampshade. Just as one can change the nature of the lamplight by changing the lampshade, one can change the Quantum Dot emitted light by changing ....Quantum Dots, a type of nanocrystal, have been shown to emit light at a very precise wavelength. Quantum dots of approximately 5 nm in diameter have been conjugated to a silica microsphere and then coated with free silica, thus encasing the Quantum Dots in a small chamber surrounding the microsphere. This structure is analogous to a light globe under a lampshade. Just as one can change the nature of the lamplight by changing the lampshade, one can change the Quantum Dot emitted light by changing the surface of the microsphere. Since the scale is so small (each microsphere is about the size of a single bacterial cell), the amount and nature of the material needed to bind to the surface to effect a detectable change is also very small, on the order of just of few tens or hundreds of molecules. This project seeks to exploit this principle to create a new class of ultra sensitive detector which can be used in many sorts of applications such as medical diagnostics and biosensing.Read moreRead less
Development Of A Sensitive Point Of Care Diagnostic Assay For Troponin I
Funder
National Health and Medical Research Council
Funding Amount
$137,650.00
Summary
This research aims to develop a diagnostic for immediate monitoring of patients presenting with chest pain, with the presumption of heart attack. The novel diagnostic platform will enable the estimation of a key indicator of heart muscle damage to be performed within a ten to fifteen minute window. This will aid speedier diagnosis and propoer triage of patients presenting with chest pain.
Development Of Anti-CXCR2 Monoclonal Antibodies For Tumour Therapy
Funder
National Health and Medical Research Council
Funding Amount
$174,867.00
Summary
New therapies to treat cancers and inflammatory diseases are urgently required. Our aim is to develop a new treatment for cancer and inflammation, by blocking the chemokine receptor CXCR2 which is central to angiogenesis (blood vessel growth) and inflammation. We have produced a highly effective monoclonal antibody (mAb) inhibitor of CXCR2, that is suitable for preclinical and clinical development. The project aims to examine the efficacy of this mAb in mouse tumour models and inflammation.
Development Of A Prototype Production System For Optical Fibre Diagnostic Probes
Funder
National Health and Medical Research Council
Funding Amount
$191,598.00
Summary
Advances in nanotechnology have led to new techniques for the precise fabrication of nanometre scale structures. A recent breakthrough by the applicants now allows high-quality nanostructures to be stamped onto the tip of low-cost optical fibre probes. When coated with silver, these sensitive probes can be used for continuous monitoring of blood glucose in diabetics and in critical care situations. This project aims to develop a prototype manufacturing system for optical fibre glucose probes.
The Development Of Store Operated Calcium Channel Monoclonal Antibody Inhibitors As A Therapeutic Option For Breast Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$230,753.00
Summary
Despite recent advances in the treatment of breast cancer, a significant proportion of women with this disease receive little benefit from currently available treatments and die from breast cancer. Hence, new therapies for the breast cancers with the poorest prognosis are needed. This grant exploits our earlier finding that a specific calcium channel is a likely therapeutic target for breast cancer. Funding from this grant will be used to develop an inhibitory monoclonal antibody to this target.
The majority of deaths from cancer are due to metastasis, which is the formation of secondary tumours at sites remote from the primary tumour. Metastasis involves conversion of some tumour cells to an invasive, migratory form in a process that is controlled by small genetic regulators known as microRNAs. In this project we will conduct experiments aimed to provide a proof of principle demonstration in mice that microRNAs can be used to block the formation of metastases.
Development Of Modified IGF-binding Proteins As Novel Anti-cancer Chemotherapeutics
Funder
National Health and Medical Research Council
Funding Amount
$77,375.00
Summary
We propose to enhance the effectiveness of current anti-cancer treatments by co-administering a protein to sequester growth factors that promote the resistance of cancer cells to chemotherapy. We aim to achieve improved destruction of breast and colorectal cancers but with reduced adverse side effects. Our in vitro data show the effectiveness of this novel co-therapeutic which is a modified form of a natural carrier protein for these growth factors. This application seeks funding to enable proof ....We propose to enhance the effectiveness of current anti-cancer treatments by co-administering a protein to sequester growth factors that promote the resistance of cancer cells to chemotherapy. We aim to achieve improved destruction of breast and colorectal cancers but with reduced adverse side effects. Our in vitro data show the effectiveness of this novel co-therapeutic which is a modified form of a natural carrier protein for these growth factors. This application seeks funding to enable proof of concept in vivo in order to attract commercial funding for clinical trials.Read moreRead less
Improved Formulations Of Anti-cancer Agents 5-Fluorouracil And Oxaliplatin Using Excipient Technology
Funder
National Health and Medical Research Council
Funding Amount
$202,973.00
Summary
Chemotherapy plays a key role in cancer treatment, however, problems persist with severe adverse toxic effects. Combinations of anti-cancer agents give better results, but these agents still have major negative effects, for example, on veins and peripheral nerves and they must be given separately. We have developed a novel, all-in-one formulation of Oxaliplatin with 5-Fluorouracil and Leucovorin, with the potential for fewer toxic effects and improved patient care.